After Hours
$
1.56
Change
-0.03 -1.89%
Volume
Volume 1,177
Aug 10, 2022, 4:53 p.m.
Quotes are delayed by 20 min
Previous close
$ 1.60
$ 1.59
Change
-0.01 -0.63%
Day low
Day high
$1.54
$1.62

52 week low
52 week high
$1.19
$7.53

Market cap
$104.64M
Average volume
2.13M
P/E ratio
N/A
Rev. per Employee
$417,328
EPS
-1.48
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on CTMX
-
CytomX Therapeutics stock price target cut to $2 from $6 at Wedbush
- Tomi Kilgore
-
CytomX Therapeutics downgraded to neutral from outperform at Wedbush
- Tomi Kilgore
-
CytomX Therapeutics downgraded to neutral from buy at Mizuho
- Tomi Kilgore
-
CytomX Therapeutics stock price target cut to $4 from $16 at Mizuho
- Tomi Kilgore
-
CytomX Therapeutics stock price target raised to $10 from $8 at Wedbush
- Tomi Kilgore
-
CytomX Therapeutics upgraded to outperform from neutral at Wedbush
- Tomi Kilgore
-
CytomX Therapeutics downgraded to neutral from outperform at Wedbush
- Tomi Kilgore
-
CytomX stock price target cut to $8 from $25 at Wedbush
- Tomi Kilgore
-
CytomX Therapeutics stock price target cut to $22 from $44 at Instinet
- Tomi Kilgore
-
CytomX Therapeutics started at buy with $38 stock price target at SunTrust RH
- Tomi Kilgore
-
5 Biotech Stocks a Pro Is Buying
- Barron's Online
-
Why a super dove could end up leading a Trumpian Fed
- Barbara Kollmeyer
-
CytomX stock rockets 35% after deal with Amgen
- Jeremy C. Owens
-
CytomX Therapeutics started at outperform with $26 stock price target at Wedbush
- Tomi Kilgore
-
CytomX stock price target raised to $32 from $21 at Instinet
- Tomi Kilgore
-
CytomX Therapeutics' stock soars 17% premarket after expanded collaboration with Bristol-Myers
- Tomi Kilgore
-
CytomX to receive $200 mln upfront payment from Bristol-Myers as part of expanded collaboration
- Tomi Kilgore
-
CytomX eligible to receive $448 mln in milestone payments from Bristol-Myers
- Tomi Kilgore
- Loading more headlines...
Analyst Ratings
-
Benzinga's Top Upgrades, Downgrades For January 5, 2018
- Benzinga.com
-
Benzinga's Top Upgrades, Downgrades For September 8, 2017
- Benzinga.com
-
Benzinga's Top Upgrades, Downgrades For March 27, 2017
- Benzinga.com
Other News on CTMX
-
CytomX Q2 2022 Earnings Preview
- Seeking Alpha
-
CytomX Therapeutics to cut workforce by about 40%
- Seeking Alpha
-
ABEO, RADA and VORB among mid-day movers
- Seeking Alpha
-
CytomX Therapeutics (CTMX) Investor Presentation - Slideshow
- Seeking Alpha
-
Notable earnings after Thursday's close
- Seeking Alpha
- Loading more headlines...
Earnings Announcement
Press Releases on CTMX
-
CytomX Therapeutics Provides Strategic Update
- GlobeNewswire
-
CytomX Therapeutics Announces New Employment Inducement Grants
- GlobeNewswire
-
CytomX Therapeutics Announces New Employment Inducement Grants
- GlobeNewswire
-
CytomX Therapeutics Announces New Employment Inducement Grants
- GlobeNewswire
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com